Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58

  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Serrano, Beatriz
  • Tous, Sara|||0000-0002-5423-7092
  • Alejo, María
  • Lloveras, Belen|||0000-0001-8659-5241
  • Quiros Blasco, Beatriz|||0000-0002-6187-3732
  • Clavero, Omar|||0000-0001-9721-6382
  • Vidal, August|||0000-0001-5727-2099
  • Ferrandiz-Pulido, Carla|||0000-0003-3688-9596
  • Pavón, Miquel Ángel
  • Holzinger, Dana
  • Halec, Gordana
  • Tommasino, Massimo
  • Quint, Wim
  • Pawlita, Michael
  • Muñoz, Nubia
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Alemany, Laia|||0000-0003-0945-6015
Many countries, mainly high- and upper-middle income, have implemented human papillomavirus (HPV) vaccination programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently licensed HPV vaccines. In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNA-positive samples were additionally subjected to HPV E6*I mRNA detection and/or p16 INK4a immunohistochemistry. For cervical cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and p16 INK4a biomarkers. The addition of HPVs 31/33/45/52/58 to HPVs 16/18/6/11 in the nonavalent HPV vaccine could prevent almost 90% of cervical cancer cases worldwide. For other sites, the nonavalent HPV vaccine could prevent 22.8% of vulvar, 24.5% of penile, 60.7% of vaginal, 79.0% of anal cancers, 21.3% of oropharyngeal, 4.0% of oral cavity, and 2.7% of laryngeal cancer cases. Our estimations suggest a potential impact of the nonavalent HPV vaccine in reducing around 90% of cervical cancer cases and a global reduction of 50% of all the cases at HPV-related cancer sites.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epidemiology of human papillomavirus-related oropharyngeal cancer in a classically low-burden region of southern Europe

  • Mena, Marisa|||0000-0003-2163-892X
  • Frias-Gomez, Jon|||0000-0002-0366-676X
  • Taberna, Miren|||0000-0002-2446-186X
  • Quirós, Beatriz|||0000-0002-6187-3732
  • Marquez, Sandra
  • Clavero, Omar|||0000-0001-9721-6382
  • Baena, Antoni.|||0000-0001-9221-8784
  • Lloveras, Belen|||0000-0001-8659-5241
  • Alejo, María
  • León i Vintró, Xavier|||0000-0001-6286-630X
  • García, Jacinto Montero
  • Mesia, Ricard|||0000-0002-3785-3563
  • Bermejo, Josep Oriol|||0000-0002-8581-9415
  • Bonfill Abella, Teresa|||0000-0003-2775-0293
  • Aguilà, Antón
  • Guix, Marta|||0000-0002-2143-0697
  • Hijano, Rafael|||0000-0001-6787-5440
  • Pavón, Miguel Ángel|||0000-0003-3677-5329
  • Torres, Montserrat A.
  • Tous, Sara|||0000-0002-5423-7092
  • Clèries, Ramon|||0000-0002-3637-4747
  • Alemany, Laia|||0000-0003-0945-6015
The incidence of human papillomavirus (HPV)-related oropharyngeal cancer is increasing in some regions. Nevertheless, the epidemiology of this disease has not been extensively investigated in southern Europe. We conducted a retrospective cohort study of patients diagnosed with primary oropharyngeal cancer from 1991 to 2016. Cancer tissues underwent histopathological evaluation, DNA quality control, HPV-DNA detection and p16 immunohistochemistry. Data were collected from medical records. Factors associated with HPV positivity and time trends were evaluated with multivariable Bayesian models. The adjusted prevalence of HPV-related cases in 864 patients with a valid HPV-DNA result was 9.7%, with HPV-DNA/p16 double positivity being considered. HPV-related oropharyngeal cancer was likely to occur in non-smokers and non-drinkers, to be located in the tonsil or diagnosed at advanced stages. Time-trend analysis showed an increasing risk of HPV-related oropharyngeal cancer in the most recent periods (5-year period increase of 30%). This increase was highest and with a clear increasing trend only in the most recent years (2012-2016). The prevalence of HPV-related oropharyngeal cancer started to sharply increase in the most recent years in our setting, as occurred two decades ago in areas where most oropharyngeal cancer cases are currently HPV-related. Our results provide a comprehensive assessment of the epidemiological landscape of HPV-related oropharyngeal cancer in a region of southern Europe.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Concordance of p16INK4a and E6*I mRNA among HPV-DNA-Positive Oropharyngeal, Laryngeal, and Oral Cavity Carcinomas from the ICO International Study

  • Mena, Marisa|||0000-0003-2163-892X
  • Wang, Xin
  • Tous, Sara|||0000-0002-5423-7092
  • Quiros Blasco, Beatriz|||0000-0002-6187-3732
  • Clavero, Omar|||0000-0001-9721-6382
  • Alejo, María
  • Morey, Francisca|||0000-0001-5329-9649
  • Taberna, Miren|||0000-0002-2446-186X
  • León i Vintró, Xavier|||0000-0001-6286-630X
  • Lloveras Rubio, Belén
  • Alos, Llucìa|||0000-0002-3460-0384
  • Mehanna, Hisham|||0000-0002-5544-6224
  • Quint, Wim
  • Pawlita, Michael
  • Tommasino, Massimo
  • Pavón, Miguel Angel
  • Muñoz, Nubia
  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Bosch José, Francesc Xavier|||0000-0002-7172-3412
  • Alemany, Laia|||0000-0003-0945-6015
Background: Tests or test algorithms for diagnosing HPV-driven oral cavity and laryngeal head and neck carcinomas (HNC) have not been yet validated, and the differences among oral cavity and laryngeal sites have not been comprehensively evaluated. We aimed to assess the utility of a diagnostic algorithm for the detection of HPV-driven oral cavity (OCC), oropharyngeal (OPC) and laryngeal (LC) carcinomas using HPV-DNA testing followed by p16 immunohistochemistry, taking E6*I mRNA detection as the reference standard. Methods: Formalin-fixed paraffin-embedded OCC, OPC, and LC carcinomas were collected from pathology archives in 29 countries. All samples were subjected to histopathological evaluation, DNA quality control, and HPV-DNA detection. All HPV-DNA-positive samples (including 78 OCC, 257 OPC, and 51 LC out of 3680 HNC with valid HPV-DNA results) were also tested for p16 immunohistochemistry and E6*I mRNA. Three different cutoffs of nuclear and cytoplasmic staining were evaluated for p16: (a).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The use of HPV16-E5, EGFR, and PEGFR as prognostic biomarkers for oropharyngeal cancer patients

  • Taberna, Miren|||0000-0002-2446-186X
  • Torres Tarrés, Montserrat
  • Alejo, María
  • Mena, Marisa|||0000-0003-2163-892X
  • Tous, Sara|||0000-0002-5423-7092
  • Marquez, Sandra
  • Pavón, Miquel A.
  • León, Xavier|||0000-0002-8393-2721
  • Garcia Lorenzo, J.|||0000-0002-6123-7808
  • Guix, Marta|||0000-0002-2143-0697
  • Hijano, Rafael|||0000-0001-6787-5440
  • Bonfill Abella, Teresa|||0000-0003-2775-0293
  • Aguilà, Antón
  • Lozano, Alicia|||0000-0003-0528-5212
  • Mesia, Ricard|||0000-0002-3785-3563
  • Alemany, Laia|||0000-0003-0945-6015
  • Bravo, Ignacio G.
Anti-epidermal-growth-factor-receptor (EGFR) therapies in combination with radiotherapy are being studied on deescalation clinical trials for HPV-related oropharyngeal cancer (OPC) patients. The HPV16-E5 oncoprotein increases recycling of activated EGFR to the cell surface, enhancing factor signal transduction. Our aim was to evaluate viral HPV16-E5 oncogene expression as well as EGFR and phosphorylated-EGFR (pEGFR), protein levels as biomarkers for clinical outcome in a retrospective cohort of OPC patients. Formalin-fixed-paraffin-embedded OPCs were collected from 1990 to 2013. OPC samples containing HPV-DNA were subject to viral E6*I mRNA detection and p16INK4a immunohistochemistry (IHC). HPV16-positive cases were evaluated for HPV16-E5 (RT-PCR) and EGFR/pEGFR (IHC). A stratified and matched random sample of HPV-negative samples was used as control and evaluated for EGFR/pEGFR. Overall survival (OS) and disease free survival (DFS) estimates were assessed for locally advanced OPC patients (stage III, IVa,b 7th edition). Among 788 OPC patient samples, 53 were double positive for HPV16-DNA/p16. HPV16-E5 expression was found in 41 of 53 samples (77.4%). EGFR expression was observed in 37.7 vs 70.8% of HPV16-positive vs HPV-negative samples, respectively; (adjusted OR = 0.15) 5% CI = 0.04-0.56]). Expression of pEGFR followed an inverse pattern with 39.6 and 24.9% detection in HPV16-positive and HPV-negative samples; (adjusted OR = 1.58 [95% CI = 0.48-5.17]). Within HPV16-positive cases, no association between HPV16-E5/EGFR nor pEGFR was observed. With a median follow-up of 39.36 months (min = 0.03 - max = 272.07), the combination of HPV status and EGFR or pEGFR expression were predictors of better OS (p < 0.001, for both) and DFS (p < 0.001 for EGFR and p = 0.003 for pEGFR). HPV16-E5 is highly expressed on HPV16-positive OPCs. Interestingly, HPV16-positive cases expressed significantly more pEGFR while HPV-negative cases expressed more EGFR. The combinations of HPV status and EGFR or pEGFR may be useful biomarkers for evaluating prognosis outcome in OPC patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HPV-relatedness definitions for classifying HPV-related oropharyngeal cancer patient do impact on TNM classification and patients' survival

  • Taberna, Miren|||0000-0002-2446-186X
  • Mena, Marisa|||0000-0003-2163-892X
  • Tous, Sara|||0000-0002-5423-7092
  • Pavón, Miquel Angel
  • Oliva, Marc|||0000-0001-5352-8130
  • León i Vintró, Xavier|||0000-0001-6286-630X
  • Garcia Lorenzo, J|||0000-0002-6123-7808
  • Guix, Marta|||0000-0002-2143-0697
  • Hijano, Rafael|||0000-0001-6787-5440
  • Bonfill Abella, Teresa|||0000-0003-2775-0293
  • Aguilà, Antón
  • Alemany, Laia|||0000-0003-0945-6015
  • Mesia, Ricard|||0000-0002-3785-3563
Given the different nature and better outcomes of oropharyngeal carcinoma (OPC) associated with human papillomavirus (HPV) infection, a novel clinical stage classification for HPV-related OPC has been accepted for the 8 edition AJCC TNM (ICON-S model). However, it is still unclear the HPV-relatedness definition with best diagnostic accuracy and prognostic value. The aim of this study was to compare different staging system models proposed for HPV-related OPC patients: 7 edition AJCC TNM, RPA stage with non-anatomic factors (Princess Margaret), RPA with N categories for nasopharyngeal cancer (MD-Anderson) and AHR-new (ICON-S), according to different HPV-relatedness definitions: HPV-DNA detection plus an additional positive marker (p16 or HPV-mRNA), p16 positivity alone or the combination of HPV-DNA/p16 positivity as diagnostic tests. A total of 788 consecutive OPC cases diagnosed from 1991 to 2013 were considered eligible for the analysis. Of these samples, 66 (8.4%) were positive for HPV-DNA and (p16 or HPV-mRNA), 83 (10.5%) were p16 positive and 58 (7.4%) were double positive for HPV-DNA/p16. ICON-S model was the staging system, which performed better in our series when using at least two biomarkers to define HPV-causality. When the same analysis was performed considering only p16-positivity, RPA stage with non-anatomic factors (Princess Margaret) has the best classification based on AIC criteria. HPV-relatedness definition for classifying HPV-related OPC patient do impact on TNM classification and patients' survival. Further studies assessing HPV-relatedness definitions are warranted to better classify HPV-related OPC patients in the era of de-escalation clinical trials.